Information  X 
Enter a valid email address

Company Name matching 'Sanofi'

Date
Time Source
Company
Announcement
29 May 2020 9:01 pm GNW   Sanofi Sanofi announces closing of Regeneron stock sale
  1:00 pm GNW   Sanofi Libtayo® (cemiplimab-rwlc) longer-term results in advanced cutaneous squamous cell carcinoma presented at ASCO 2020 show durable responses that deepen over time
  6:00 am GNW   Sanofi Sanofi names new leaders to Executive Committee
28 May 2020 5:05 pm GNW   Sanofi Sanofi’s Board of Directors notes the resignation of Emmanuel Babeau and coopts Gilles Schnepp as Independent Director
27 May 2020 12:55 am GNW   Sanofi Sanofi announces pricing of Regeneron stock offering
26 May 2020 4:40 pm GNW   Sanofi Sanofi: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 to 11 years with moderate-to-severe atopic dermatitis
25 May 2020 5:45 pm GNW   Sanofi Sanofi intends to sell its equity investment in Regeneron; confirms no change to ongoing collaboration
22 May 2020 11:25 pm GNW   Sanofi Dupixent® (dupilumab) eosinophilic esophagitis trial meets both co-primary endpoints
18 May 2020 6:00 am GNW   Sanofi Sanofi to highlight pipeline programs in a series of interactive virtual sessions leading to a R&D day event
14 May 2020 6:00 am GNW   Sanofi FDA grants priority review of sutimlimab, potential first approved treatment of hemolysis in adult patients with Cold Agglutinin Disease
12 May 2020 6:00 am GNW   Sanofi Sarclisa® (isatuximab) Phase 3 IKEMA trial meets primary endpoint early in patients with relapsed multiple myeloma
05 May 2020 6:00 am GNW   Sanofi Libtayo® (cemiplimab) shows clinically meaningful and durable responses in second-line advanced basal cell carcinoma
28 Apr 2020 5:06 pm GNW   Sanofi Sanofi: Annual General Meeting of April 28, 2020
27 Apr 2020 12:00 pm GNW   Sanofi Sanofi: Phase 3 trial of Libtayo® (cemiplimab) as monotherapy for first-line advanced non-small cell lung cancer stopped early due to highly significant improvement in overall survival
  11:58 am GNW   Sanofi Sanofi and Regeneron provide update on U.S. Phase 2/3 adaptive-designed trial in hospitalized COVID-19 patients
24 Apr 2020 6:30 am GNW   Sanofi Sanofi at forefront of fight against COVID-19 in Q1 2020
  6:00 am GNW   Sanofi FDA approves MenQuadfiTM, the latest innovation in meningococcal (MenACWY) vaccination
23 Apr 2020 6:00 am GNW   Sanofi Sanofi brain-penetrant BTK inhibitor significantly reduced disease activity in Phase 2 trial in relapsing multiple sclerosis
17 Apr 2020 6:00 am GNW   Sanofi Sanofi to present Phase 2 detailed results of its brain-penetrant BTK inhibitor in relapsing multiple sclerosis
16 Apr 2020 1:00 pm GNW   Sanofi Sanofi and Luminostics to join forces on developing breakthrough COVID-19 smartphone-based self-testing solution
14 Apr 2020 12:00 pm GNW   Sanofi Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19
06 Apr 2020 10:00 pm GNW   Sanofi Sanofi finalizes Praluent® (alirocumab) restructuring with Regeneron
  7:11 pm GNW   Sanofi Sanofi successfully prices taps on outstanding bond issues for EUR 500 million
03 Apr 2020 6:30 am GNW   Sanofi Sanofi: Availability of the Pre-quarterly Results Communication
  6:00 am GNW   Sanofi Sanofi: Dupixent® (dupilumab) Phase 3 data show significant improvement in severe atopic dermatitis for children aged 6 to 11 years
01 Apr 2020 6:00 am GNW   Sanofi Sanofi: Information on Sanofi’s Shareholder General Meeting of Tuesday, April 28, 2020
30 Mar 2020 6:00 am GNW   Sanofi Sanofi: First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19
27 Mar 2020 6:05 am GNW   Sanofi Sanofi receives positive CHMP opinion for Sarclisa® (isatuximab) for the treatment of relapsed and refractory multiple myeloma
  6:00 am GNW   Sanofi Sanofi and Translate Bio collaborate to develop novel mRNA vaccine candidate against COVID-19
24 Mar 2020 9:00 pm GNW   Sanofi Sanofi successfully prices EUR 1.5 billion of bond issue
05 Mar 2020 10:28 pm GNW   Sanofi Sanofi : Filing of the 2019 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
04 Mar 2020 5:38 pm GNW   Sanofi Sanofi's Board of Directors proposes the appointment of Rachel Duan and Lise Kingo as independent directors
02 Mar 2020 6:51 pm GNW   Sanofi Sanofi : FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma
24 Feb 2020 3:03 pm GNW   Sanofi Sanofi to create new industry leading European company to provide active pharmaceutical ingredients (API*)
18 Feb 2020 3:00 pm GNW   Sanofi Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine
06 Feb 2020 6:30 am GNW   Sanofi Sanofi delivers strong 2019 business EPS growth of 6.8% at CER
  6:00 am GNW   Sanofi Sanofi : Sanofi brain-penetrant BTK inhibitor meets primary endpoint of Phase 2 trial in relapsing multiple sclerosis
30 Jan 2020 6:00 am GNW   Sanofi Sanofi : Positive topline results demonstrated by olipudase alfa, first and only investigational therapy in late-stage development for acid sphingomyelinase deficiency
28 Jan 2020 6:00 am GNW   Sanofi Sanofi : FDA accepts for priority review Dupixent® (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis
23 Jan 2020 1:52 pm GNW   Sanofi Sanofi : Sanofi Completes Acquisition of Synthorx, Inc.
20 Jan 2020 6:00 am GNW   Sanofi Sanofi : Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Synthorx
09 Jan 2020 6:30 am GNW   Sanofi Sanofi : Availability of the Pre-quarterly Results Communication
23 Dec 2019 6:00 am GNW   Sanofi Sanofi commences tender offer for acquisition of Synthorx, Inc.
10 Dec 2019 1:30 pm GNW   Sanofi Sanofi and Regeneron announce intent to restructure Antibody collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab)
  12:30 pm GNW   Sanofi Sanofi : Positive results presented from pivotal Phase 3 trial of sutimlimab in people with cold agglutinin disease
09 Dec 2019 9:42 pm GNW   Sanofi Sanofi CEO unveils new strategy to drive innovation and growth
04 Nov 2019 10:30 pm GNW   Sanofi Sanofi : FDA approves Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for adults 65 years of age and older
  6:00 am GNW   Sanofi Sanofi : Positive results in Phase 3 trial for Toujeo® in children and adolescents with type 1 diabetes
31 Oct 2019 6:30 am GNW   Sanofi Sanofi Q3 well on track
29 Oct 2019 12:15 pm GNW   Sanofi Sanofi : Dupixent® (dupilumab) now approved in European Union for severe chronic rhinosinusitis with nasal polyposis
15 Oct 2019 6:00 am GNW   Sanofi Sanofi opens its first digitally-enabled, continuous manufacturing facility; ushers in next generation of biotech manufacturing
01 Oct 2019 9:30 pm GNW   Sanofi Sanofi : Availability of the Pre-quarterly Results Communication
30 Sep 2019 3:30 pm GNW   Sanofi Sanofi : New England Journal of Medicine publishes data showing improved survival with Jevtana® (cabazitaxel) over second androgen receptor-targeted agent in metastatic castration-resistant prostate cancer
20 Sep 2019 11:48 am GNW   Sanofi Sanofi : CHMP recommends approval of Dupixent® (dupilumab) for severe chronic rhinosinusitis with nasal polyposis  
16 Sep 2019 6:00 am GNW   Sanofi Sanofi and Abbott partner to integrate glucose sensing and insulin delivery technologies to help change the way diabetes is managed
28 Aug 2019 9:35 pm GNW   Sanofi Sanofi : U.S. District Court invalidates Amgen patent claims targeting PCSK9
06 Aug 2019 6:05 am GNW   Sanofi Sanofi : Dupixent® (dupilumab) showed positive topline results in Phase 3 trial of children aged 6 to 11 years with severe atopic dermatitis
  6:00 am GNW   Sanofi Sanofi : Dupixent® (dupilumab) approved by European Commission for adolescents with moderate-to-severe atopic dermatitis
29 Jul 2019 6:30 am GNW   Sanofi Sanofi delivered solid growth in Q2 2019
26 Jul 2019 9:05 pm GNW   Sanofi Sanofi :  Sanofi provides update on ZynquistaTM (sotagliflozin) type 2 diabetes Phase 3 program and collaboration with Lexicon


Company Announcements Archive »

 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t